A Second-Generation MicroRNA-Based Assay for Diagnosing Tumor Tissue Origin

Meiri, Eti; Mueller, Wolf; Rosenwald, Shai; Zepeniuk, Merav; Klinke, E.; Edmonston, Tina Bocker; M, Werner; Laß, Ulrike; Barshack, Iris; Feinmesser, Meora; Huszar, Monica; Fogt, Franz; Ashkenazi, Karin; Sanden, Mats; Goren, Eran; Dromi, Nir; Zion, Orit; Burnstein, Ilanit; Chajut, Ayelet; Spector, Yael; Aharonov, Ranit

doi:10.1634/theoncologist.2011-0466

Cited by 139 publications

(101 citation statements)

References 31 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This research group recently developed a second-generation microarray assessing the levels of 64 miRNAs to identify 42 tumor types. 25 The assay was validated on a set of 509 blinded samples and showed a sensitivity of 85%.…”

Section: Occ-1mentioning

confidence: 99%

Occult Primary, Version 3.2014

Ettinger

Handorf

Agulnik³

et al. 2014

J Natl Compr Canc Netw

View full text Add to dashboard Cite

The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation. (J Natl Compr Canc Netw 2014;12:969-974) Occult Primary, Version 3.2014 CE Authors:Deborah J. Moonan, RN, BSN, Director, Continuing Education & Grants, NCCN, has disclosed that she has no relevant financial relationships. Ann Gianola, MA, Manager, Continuing Education & Grants, NCCN, has disclosed that she has no relevant financial relationships. Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships. Individuals Who Provided Content Development and/or Authorship Assistance:David S. Ettinger, MD, panel chair, has disclosed that he has no relevant financial relationships. Charles R. Handorf, MD, PhD, panel vice-chair, has disclosed that he has no relevant financial relationships. Mary Anne Bergman, Guidelines Coordinator, has disclosed that she has no relevant financial relationships. Deborah A. Freedman-Cass, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.

show abstract

Section: Occ-1mentioning

confidence: 99%

Occult Primary, Version 3.2014

Ettinger

Handorf

Agulnik³

et al. 2014

J Natl Compr Canc Netw

View full text Add to dashboard Cite

show abstract

“…Gene expression profiling assays correctly identified the site of origin in 85% of cases in blinded studies of tumors of known origin, and was found to favorably compare with IHC staining (17,18). The best use of gene expression profiling to form a diagnosis appears to be for cases with inconclusive IHC staining.…”

Section: Discussionmentioning

confidence: 92%

“…The CancerTYPE ID assay is a 92-gene reverse transcription-polymerase chain reaction assay that allows the identification of 30 main tumor types and 54 subtypes (17). There is also another gene expression profiling assay currently commercially available, which uses 64 tissue-specific microRNAs to enable the identification of 42 tumor types, using a microarray technology known as the Cancer Origin Test (Rosetta Genomics, Rehovot, Israel) (18). These two assays were validated using biopsies of tumors from known primary sites.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Gene expression profiling and its use in adenocarcinomas of unknown primary origin: A case report

et al. 2015

View full text Add to dashboard Cite

Abstract. Carcinomas of unknown primary origin account for 3-5% of all malignancies. The current literature suggests that metastatic dissemination is able to occur in the absence of primary tumor growth. In metastatic disease that is difficult to diagnose, the origin usually remains unknown even after an exhaustive evaluation of immunohistochemistry (IHC) markers. In the current study, a 49-year-old male presented with lymph nodes metastases of unknown origin. The excisional biopsy of an inguinal node revealed an adenocarcinoma growth pattern, but the IHC could not determine the primary origin. A gene profiling test was performed to complete the diagnosis and a salivary gland adenocarcinoma was diagnosed with 90% probability. Subsequently, the patient underwent appropriate chemotherapy for salivary gland adenocarcinoma, and exhibited an improved partial response. The present case study highlights the importance of an accurate diagnosis of the primary tumor and the use of all the current tools available in order to provide patients with the best treatment possible.

show abstract

“…In fact, some diagnostic tests employing ncRNA are already commercially available 13,[95][96][97] , with many others expected to follow.…”

Section: Five-year Viewmentioning

confidence: 99%

High-throughput profiling for discovery of non-coding RNA biomarkers of lung disease

McKiernan

Greene

2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Abstract:In respiratory medicine there is a need for clinical biomarkers for diagnosis, prognosis and assessment of response to therapy. Non-coding RNA is expressed in all human cells: two major classes, ncRNA and microRNA, are detectable extracellularly in the circulation and other biofluids. Altered ncRNA expression is associated with lung disease; collectively this indicates that ncRNA represents a potential biomarker class. This article presents and compares existing platforms for detection and quantification of ncRNA, specifically hybridization, qRT-PCR and RNA sequencing, and outlines methods for data interpretation and normalization. Each approach has merits and shortcomings, which can affect the choice of method when embarking on a biomarker study. Biomarker properties and pre-analytical considerations for ncRNA profiling are also presented. Since a variety of profiling approaches are available, careful study and experimental design are important. Finally challenges and goals for reliable, standardized high-throughput ncRNA profiling in biofluids as lung disease biomarkers are reviewed.

show abstract

A Second-Generation MicroRNA-Based Assay for Diagnosing Tumor Tissue Origin

Cited by 139 publications

References 31 publications

Occult Primary, Version 3.2014

Occult Primary, Version 3.2014

Gene expression profiling and its use in adenocarcinomas of unknown primary origin: A case report

High-throughput profiling for discovery of non-coding RNA biomarkers of lung disease

Contact Info

Product

Resources

About